Affordable Access

deepdyve-link
Publisher Website

Association of tibolone and dementia risk: a cohort study using Korean claims data.

Authors
  • Han, Minjung1
  • Chang, Jooyoung2
  • Choi, Seulggie2
  • Cho, Yoosun1
  • Lee, Gyeongsil1
  • Park, Sang Min1, 2
  • 1 Department of Family Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea. , (North Korea)
  • 2 Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, South Korea. , (North Korea)
Type
Published Article
Journal
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
Publication Date
Jun 01, 2021
Volume
37
Issue
6
Pages
567–571
Identifiers
DOI: 10.1080/09513590.2020.1843624
PMID: 33150798
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Few studies have examined whether tibolone (TIB), a type of hormone replacement therapy widely used in Asia and Europe, affects dementia risk in postmenopausal women. Our study aims to investigate the association of TIB and dementia risk in Korean women aged 50-80 years. A population-based longitudinal study was conducted using the Korean National Health Insurance Service claims database merged with national health examination data from 2002 to 2015. Among 13,110 participants, exposure to TIB was determined using the standardized defined daily dose (DDD) system from 2003 to 2007. Starting from 2007, participants were followed up for overall dementia, Alzheimer's disease (AD) and vascular dementia (VD) until 2015. Cox proportional hazards regression was used to determine the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) of dementia according to TIB use. TIB use was not significantly associated with the risk of total dementia (aHR = 1.040; 95% CI = 0.734-1.472; p = .827), AD (aHR = 0.949; 95% CI = 0.652-1.381; p = .785) and VD (aHR = 1.245; 95% CI = 0.631-2.457; p = .528). Our results suggest that TIB use does not have a significant association with dementia risk. Further randomized controlled trials are necessary to elucidate the role of exogenous hormones in the development of dementia.

Report this publication

Statistics

Seen <100 times